- "Albumin & Creatinine Tests Market by Product (Analyzers, Cartridges (PoC, Tabletop), Dipsticks, Kits, Reagents), Type (Blood & Urine Creatinine, Urine Albumin, Glycated Albumin), Enduser (Hospital, Diagnostic & Research Labs) -.
According to the new market research report "Albumin & Creatinine Tests Market by Product (Analyzers, Cartridges (PoC, Tabletop), Dipsticks, Kits, Reagents), Type (Blood & Urine Creatinine, Urine Albumin, Glycated Albumin), Enduser (Hospital, Diagnostic & Research Labs) - Global Forecast to 2025", published by MarketsandMarkets™, the ACR Test Market is projected to reach USD 2,103 million by 2025 from USD 987 million in 2020, at a CAGR of 16.3%.
Browse in-depth TOC on "Albumin and Creatinine Tests Market"131 – Tables32 – Figures159 – Pages
Download PDF Brochure:- Albumin & Creatinine Tests Market
The growth of the global albumin & creatinine tests market is driven by factors such as the growing prevalence of kidney disorders, the rising adoption of POC diagnostics, and the increasing prevalence of chronic conditions.
The dipsticks & kits products segment accounted for the largest share of the ACR Tests Market, by product segment, in 2019
Based on product, the albumin and creatinine tests market is segmented into dipsticks & kits, analyzers, cartridges, and reagents & other consumables. In 2019, the dipsticks & kits segment accounted for the largest share in this market. The frequent purchase of these products compared to instruments like analyzers and cartridges and the increasing use of kit-based rapid techniques for albumin & creatinine tests drive market growth.
Urine Tests segment to register the highest growth rate during the forecast period
Based on type, the albumin & creatinine tests market is segmented into urine tests and blood & serum creatinine tests. In 2019, urine tests accounted for the largest share in this market. Factors such as the rapid growth in the diagnostics segment and the increasing demand for rapid and easy-to-use urine tests drive the growth of this segment.
Request Sample Pages: -Albumin & Creatinine Tests Market
North America is the largest regional market for albumin & creatinine tests market
The global ACR Test Market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2019, North America accounted for the largest share in the global market. The large share of this regional segment can primarily be attributed to the growth in demand for rapid urine tests, increasing prevalence of chronic conditions leading to various kidney diseases, rising government initiatives, and growing geriatric population.
The major players operating in this ACR Tests Market are Thermo Fisher Scientific, Inc. (US), Roche Diagnostics (Switzerland), PromoCell GmbH (Germany), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics (US), Randox Laboratories (UK), FUJIFILM Wako Pure Chemical Corporation (Japan), Abbexa Ltd. (UK), ACON Laboratories, Inc. (US), Arbor Assays Inc. (US), ARKRAY Global Business Inc. (Japan), Aviva Systems Biology (US), Axxora, LLC (UK), BioAssay Systems (US), Nova Biomedical (US), Quantimetrix Corporation (US), RayBiotech Inc. (US), Sekisui Diagnostics PEI Inc. (US), Teco Diagnostics (US), Tulip Diagnostics (India), ulti med Products GmbH (Germany), and URIT Medical Electronic Co., Ltd. (CHINA).
Browse Related Reports:
Urinalysis Market by Product (Dipsticks, Pregnancy & Fertility Kits, Reagents, Disposables, Automated, Semi-automated, PoC Analyzers), Application (UTI, Diabetes, Pregnancy), End User (Hospital, Labs, Homecare) & Test Type - Global Forecast to 2024https://www.marketsandmarkets.com/Market-Reports/urinalysis-systems-market-153479294.html
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.